Latest News by Industry
EXETER, N.H.--(BUSINESS WIRE)--Nov 2, 2022--
Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced third quarter 2022 financial results.
Third Quarter 2022 Summary
“Our revenue increased sequentially from the second quarter to the third quarter which is not typical given the seasonality in our business,” said Joseph Army, President and CEO. “Growth was driven primarily by consistent monthly improvement in U.S. disposables turn rates, reaching 60% of the three-year pre-COVID historical average in the third quarter, and the ongoing launch of our new product platform HVT 2.0. In addition, we executed on our path to profitability initiatives and completed actions to decrease our annual cash operating expense from $100 million in 2021 to $60 million to $62 million in 2023 while still preserving future growth drivers. We are on track to complete the move of operations to Mexico by year-end which we believe will improve our gross margins to 60% once we work through our higher costed inventory and initial production builds.”
Results for the Three Months September 30, 2022
The following table reflects the Company’s net revenue for the three months ended September 30, 2022 and 2021:
|
| Three Months Ended September 30, |
|
|
|
|
|
|
| |||||||||||||||
|
| 2022 |
|
| 2021 |
|
| Change |
| |||||||||||||||
|
| (in thousands, except percentages) |
| |||||||||||||||||||||
|
| Amount |
|
| % of Revenue |
|
| Amount |
|
| % of Revenue |
|
| $ |
|
| % |
| ||||||
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Capital (product & lease revenue) |
| $ | 1,993 |
|
|
| 14.7 | % |
| $ | 15,113 |
|
|
| 39.7 | % |
| $ | (13,120 | ) |
|
| (86.8 | )% |
Disposables |
|
| 9,463 |
|
|
| 69.9 | % |
|
| 21,674 |
|
|
| 56.9 | % |
|
| (12,211 | ) |
|
| (56.3 | )% |
Service and other |
|
| 2,089 |
|
|
| 15.4 | % |
|
| 1,328 |
|
|
| 3.4 | % |
|
| 761 |
|
|
| 57.3 | % |
Total net revenue |
| $ | 13,545 |
|
|
| 100.0 | % |
| $ | 38,115 |
|
|
| 100.0 | % |
| $ | (24,570 | ) |
|
| (64.5 | )% |
Net revenue for the third quarter of 2022 was $13.5 million. Capital and disposables revenue were lower in the third quarter of 2022 as the Delta related COVID surge in the third quarter of 2021 drove significant worldwide demand for the Company’s products, which did not repeat itself in the current quarter. Worldwide disposables revenue in the third quarter of 2021 grew 66.2% over the third quarter of 2020.
Revenue information by geography is summarized as follows:
|
| Three Months Ended September 30, |
|
|
|
|
|
|
| |||||||||||||||
|
| 2022 |
|
| 2021 |
|
| Change |
| |||||||||||||||
|
| (in thousands, except percentages) |
| |||||||||||||||||||||
|
| Amount |
|
| % of Revenue |
|
| Amount |
|
| % of Revenue |
|
| $ |
|
| % |
| ||||||
United States |
| $ | 11,063 |
|
|
| 81.7 | % |
| $ | 32,950 |
|
|
| 86.4 | % |
| $ | (21,887 | ) |
|
| (66.4 | )% |
International |
|
| 2,482 |
|
|
| 18.3 | % |
|
| 5,165 |
|
|
| 13.6 | % |
|
| (2,683 | ) |
|
| (51.9 | )% |
Total net revenue |
| $ | 13,545 |
|
|
| 100.0 | % |
| $ | 38,115 |
|
|
| 100.0 | % |
| $ | (24,570 | ) |
|
| (64.5 | )% |
Gross profit and gross margin for the third quarter of 2022 was $1.9 million and 13.8%, respectively. In the third quarter of 2022, gross margin was negatively impacted by inventory reserves, write-offs related to the transition from the Precision Flow platform to the HVT 2.0 platform and lower revenue and production levels. Excluding the impact of inventory reserves and write-offs related to the transition from the Precision Flow product platform to the HVT 2.0 platform, gross margin would have been 29.5%.
Total operating expenses were $24.8 million in the third quarter of 2022, a decrease of $6.9 million as compared to the same period last year. Non-GAAP cash operating expenses, excluding impairment charges, loss on disposal of property and equipment, depreciation and amortization, stock-based compensation expense, severance accruals recorded and change in the value of contingent consideration, were $19.5 million in the third quarter of 2022 compared to $30.6 million in the third quarter of 2021 and $21.7 million in the second quarter of 2022. The decreases in operating expenses and Non-GAAP cash operating expenses were primarily due to cost saving measures in connection with the Company’s path-to-profitability initiatives. Operating expenses in the third quarter of 2022 include a non-cash impairment charge of $2.1 million related to the operating lease right-of-use assets, property and equipment recorded in connection with the Company’s decision to cease future commercial investments in Vapotherm Access and RespirCare funding.
Net loss for the third quarter of 2022 was $26.2 million, or $0.98 per share, compared to $13.6 million, or $0.52 per share, in the third quarter of 2021. Net loss per share was based on 26,697,226 and 25,987,648 weighted average shares outstanding for the third quarter of 2022 and 2021, respectively. Net loss for the third quarter of 2022 includes a non-cash impairment charge of $2.1 million related to the long-lived assets recorded in connection with the acquisitions of HGE and RespirCare.
Adjusted EBITDA was negative $17.7 million for the third quarter of 2022 as compared to negative $10.7 million for the third quarter of 2021. The increase in Adjusted EBITDA loss was primarily due to lower revenue and gross margin on a year over year basis.
Cash Position
Cash and cash equivalents were $28.7 million as of September 30, 2022 compared to $49.9 million as of June 30, 2022. The decrease in cash in the third quarter of 2022 was due to the net loss.
Fiscal 2022 Outlook
For fiscal 2022, the Company expects net revenue to be in the range of $64 million to $66 million. This guidance reflects a light flu season which typically begins in the fourth quarter in the U.S. This guidance does not reflect any significant COVID impact. The Company’s guidance assumes U.S. disposable utilization rates of 60% of the three-year pre-COVID historical average for the fourth quarter which is consistent with what the Company saw in the third quarter. The Company’s guidance assumes 70-75% of the worldwide fourth quarter 2022 revenue will be driven by disposables revenue and 25-30% from capital, service, and other revenue. The Company expects U.S. revenue to account for 80% of total worldwide revenue in the fourth quarter. The decrease in revenue guidance from guidance provided last quarter was due to third quarter results, near-term headwinds in the form of longer worldwide capital equipment sales cycles and the elimination of commercial investments in Vapotherm Access and RespirCare.
For fiscal 2022, gross margin is expected to be in the range of 22% to 24%, a decrease from the previous range of 30% to 32% due to inventory reserves and write-offs related to the transition from our Precision Flow product to HVT 2.0 and lower revenue and production levels.
For fiscal 2022, operating expenses excluding impairment charges are expected to be in the range of $94 million to $96 million, a decrease from the previous range of $97 million to $100 million.
For fiscal 2022, operating expenses excluding impairment charges, depreciation and amortization, stock-based compensation expense, change in the value of contingent consideration and the impact of severance accruals are expected to be in the range of $83 million to $85 million, a decrease from the previous range of $84 million to $86 million. The Company expects fourth quarter of 2022 operating expenses excluding impairment charges, depreciation and amortization, stock-based compensation expense, change in the value of contingent consideration and the impact of severance accruals of between $16 million to $18 million.
The Company is evaluating various capital raising options while it continues to execute on its path-to-profitability initiative which includes converting $20 million of excess inventory into cash as it increases its inventory turn rates to 4 turns/year, which the Company has demonstrated in the past. The Company believes the combination of additional capital and converting of up to $20 million of inventory into cash will allow the Company to fund its business through 2023 and get it to Adjusted EBITDA positive in the fourth quarter of 2023.
Conference Call
Management will host a conference call at 4:30 p.m. Eastern Time on November 2, 2022 to discuss the results of the quarter with a question and answer session. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.vapotherm.com/events-and-presentations/events. The webcast replay will be available on the Vapotherm website for 12 months following completion of the call. A replay of this conference call will be available by telephone through November 9, 2022 by dialing +1 (800) 770-2030 in the U.S. or +1 (647) 362-9199 outside of the U.S. The replay access code is 6585549.
Website Information
Vapotherm routinely posts important information for investors on the Investor Relations section of its website, http://investors.vapotherm.com/. Vapotherm intends to use this website as a means of disclosing material, non-public information and for complying with Vapotherm’s disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of Vapotherm’s website, in addition to following Vapotherm’s press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Vapotherm’s website is not incorporated by reference into, and is not a part of, this document.
Non-GAAP Financial Measures
This press release includes non-GAAP financial measures, including EBITDA, Adjusted EBITDA, operating expenses excluding impairment charges, loss on disposal of property and equipment, depreciation and amortization, stock-based compensation expense, change in the value of contingent consideration and the impact of severance accruals recorded, which non-GAAP measures differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). EBITDA represents net loss less interest expense, net, income tax provision or benefit, and depreciation and amortization, and Adjusted EBITDA represents EBITDA as adjusted for the impact of foreign currency loss or gain, change in fair value of contingent consideration, stock-based compensation expense, and impairment of long lived and intangible assets. Since these adjustments to the GAAP measures are highly variable, difficult to predict and of a size that could have substantial impact on Vapotherm’s reported results of operations for a period, Vapotherm cannot provide without unreasonable effort a quantitative reconciliation to the most directly comparable GAAP measures for its 2022 financial guidance regarding operating expenses, excluding impairment charges, and operating expenses, excluding impairment charges, depreciation and amortization, stock-based compensation expense, change in the value of contingent consideration, loss on disposal of property and equipment and the impact of severance accruals. The Company has reconciled all historical non-GAAP financial measures with the most directly comparable GAAP financial measures in tables accompanying this release.
These non-GAAP financial measures are presented because the Company believes they are useful indicators of its operating performance. Management uses Adjusted EBITDA and non-GAAP operating expenses, excluding certain items, as measures of the Company’s operating performance and for planning purposes, including the preparation of the Company’s annual operating budget and financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company believes Adjusted EBITDA is useful to its management and investors as a measure of comparative operating performance from period to period.
These non-GAAP financial measures should not be considered alternatives to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP. They should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as tax payments, debt service requirements, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our capital expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating Adjusted EBITDA, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in this presentation. The Company’s presentation of Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using Adjusted EBITDA and other non-GAAP financial measures on a supplemental basis. The Company’s definition of Adjusted EBITDA is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.
About Vapotherm
Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The Company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 3.6 million patients have been treated with the use of Vapotherm high velocity therapy® systems. For more information, visit www.vapotherm.com.
Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. The Precision Flow system’s mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995, including statements about the Company’s expected net revenue, gross margin and operating expenses for fiscal year 2022, its expectations to execute on its path-to-profitability initiative, raise additional capital, convert $20 million of excess inventory into cash, increase its inventory turn rates to 4 turns/year and fund its business through 2023 and get it to Adjusted EBITDA positive in the fourth quarter of 2023. In some cases, you can identify forward-looking statements by terms such as “expect,” “continue,” “plan,” “intend,” “will,” “outlook,” “guidance,” or “typically,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words, and the use of future dates. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include, but are not limited to the following: Vapotherm has incurred losses in the past and may be unable to achieve or sustain profitability in the future or achieve its 2022 financial guidance; risks associated with the move of its manufacturing operations to Mexico; Vapotherm’s ability to raise additional capital to fund its existing commercial operations, develop and commercialize new products, and expand its operations; Vapotherm’s ability to comply with its $20 million minimum cash covenant, execute on its path-to-profitability initiative, convert $20 million of excess inventory into cash, increase its inventory turn rates to 4 turns/year and fund its business through 2023 and get it to Adjusted EBITDA positive in the fourth quarter of 2023; Vapotherm’s dependence on sales generated from its Precision Flow systems, competition from multi-national corporations who have significantly greater resources than Vapotherm and are more established in the respiratory market; the ability for Precision Flow systems to gain increased market acceptance; Vapotherm’s inexperience directly marketing and selling its products; the potential loss of one or more suppliers and dependence on its new third party manufacturer; Vapotherm’s susceptibility to seasonal fluctuations; Vapotherm’s failure to comply with applicable United States and foreign regulatory requirements; the failure to obtain U.S. Food and Drug Administration or other regulatory authorization to market and sell future products or its inability to secure, maintain or enforce patent or other intellectual property protection for its products; the impact of the COVID-19 pandemic on its business, including its supply chain, and the other risks and uncertainties included under the heading “Risk Factors” in Vapotherm’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the Securities and Exchange Commission on February 24, 2022 and Vapotherm’s most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 as filed with the Securities and Exchange Commission on November 2, 2022, and in any subsequent filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Vapotherm’s views as of the date hereof, and Vapotherm does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
Financial Statements:
VAPOTHERM, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share amounts) | ||||||||
|
| September 30, 2022 |
|
| December 31, 2021 |
| ||
|
| (unaudited) |
|
|
|
| ||
Assets |
|
|
|
|
|
| ||
Current assets |
|
|
|
|
|
| ||
Cash and cash equivalents |
| $ | 28,709 |
|
| $ | 57,071 |
|
Accounts receivable, net |
|
| 8,136 |
|
|
| 10,909 |
|
Inventories, net |
|
| 36,433 |
|
|
| 36,562 |
|
Prepaid expenses and other current assets |
|
| 3,201 |
|
|
| 5,205 |
|
Total current assets |
|
| 76,479 |
|
|
| 109,747 |
|
Property and equipment, net |
|
| 25,694 |
|
|
| 22,157 |
|
Operating lease right-of-use assets |
|
| 6,676 |
|
|
| 7,045 |
|
Restricted cash |
|
| 1,109 |
|
|
| 253 |
|
Goodwill |
|
| 494 |
|
|
| 15,300 |
|
Intangible assets, net |
|
| 25 |
|
|
| 4,398 |
|
Deferred income tax assets |
|
| 32 |
|
|
| 78 |
|
Other long-term assets |
|
| 2,115 |
|
|
| 1,107 |
|
Total assets |
| $ | 112,624 |
|
| $ | 160,085 |
|
Liabilities and Stockholders’ (Deficit) Equity |
|
|
|
|
|
| ||
Current liabilities |
|
|
|
|
|
| ||
Accounts payable |
| $ | 1,507 |
|
| $ | 5,923 |
|
Contract liabilities |
|
| 1,478 |
|
|
| 2,081 |
|
Accrued expenses and other current liabilities |
|
| 16,707 |
|
|
| 28,559 |
|
Revolving loan facility |
|
| - |
|
|
| 6,608 |
|
Total current liabilities |
|
| 19,692 |
|
|
| 43,171 |
|
Long-term loans payable, net |
|
| 96,815 |
|
|
| 39,726 |
|
Other long-term liabilities |
|
| 7,018 |
|
|
| 10,521 |
|
Total liabilities |
|
| 123,525 |
|
|
| 93,418 |
|
Commitments and contingencies |
|
|
|
|
|
| ||
Stockholders’ (deficit) equity |
|
|
|
|
|
| ||
Preferred stock ($0.001 par value) 25,000,000 shares authorized; no shares issued |
|
| - |
|
|
| - |
|
Common stock ($0.001 par value) 175,000,000 shares authorized as of |
|
| 27 |
|
|
| 26 |
|
Additional paid-in capital |
|
| 458,023 |
|
|
| 443,358 |
|
Accumulated other comprehensive (loss) income |
|
| (386 | ) |
|
| 26 |
|
Accumulated deficit |
|
| (468,565 | ) |
|
| (376,743 | ) |
Total stockholders’ (deficit) equity |
|
| (10,901 | ) |
|
| 66,667 |
|
Total liabilities and stockholders’ (deficit) equity |
| $ | 112,624 |
|
| $ | 160,085 |
|
VAPOTHERM, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share amounts) | ||||||||||||||||
|
| Three Months Ended September 30, |
|
| Nine Months Ended September 30, |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
|
| (unaudited) |
|
| (unaudited) |
| ||||||||||
Net revenue |
| $ | 13,545 |
|
| $ | 38,115 |
|
| $ | 48,138 |
|
| $ | 91,048 |
|
Cost of revenue |
|
| 11,682 |
|
|
| 19,291 |
|
|
| 36,018 |
|
|
| 45,649 |
|
Gross profit |
|
| 1,863 |
|
|
| 18,824 |
|
|
| 12,120 |
|
|
| 45,399 |
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Research and development |
|
| 4,382 |
|
|
| 3,979 |
|
|
| 16,241 |
|
|
| 13,466 |
|
Sales and marketing |
|
| 11,460 |
|
|
| 20,465 |
|
|
| 36,615 |
|
|
| 47,169 |
|
General and administrative |
|
| 6,477 |
|
|
| 7,262 |
|
|
| 20,754 |
|
|
| 23,948 |
|
Impairment of goodwill |
|
| - |
|
|
| - |
|
|
| 14,701 |
|
|
| - |
|
Impairment of long-lived and intangible assets |
|
| 2,139 |
|
|
| - |
|
|
| 6,175 |
|
|
| - |
|
Loss on disposal of property and equipment |
|
| 321 |
|
|
| - |
|
|
| 321 |
|
|
| - |
|
Total operating expenses |
|
| 24,779 |
|
|
| 31,706 |
|
|
| 94,807 |
|
|
| 84,583 |
|
Loss from operations |
|
| (22,916 | ) |
|
| (12,882 | ) |
|
| (82,687 | ) |
|
| (39,184 | ) |
Other (expense) income |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Interest expense |
|
| (3,276 | ) |
|
| (647 | ) |
|
| (7,872 | ) |
|
| (1,960 | ) |
Interest income |
|
| 56 |
|
|
| 21 |
|
|
| 113 |
|
|
| 74 |
|
Foreign currency loss |
|
| (73 | ) |
|
| (58 | ) |
|
| (188 | ) |
|
| (188 | ) |
Loss on extinguishment of debt |
|
| - |
|
|
| - |
|
|
| (1,114 | ) |
|
| - |
|
Other |
|
| - |
|
|
| - |
|
|
| - |
|
|
| 18 |
|
Net loss before income taxes |
| $ | (26,209 | ) |
| $ | (13,566 | ) |
| $ | (91,748 | ) |
| $ | (41,240 | ) |
(Benefit) provision for income taxes |
|
| (8 | ) |
|
| - |
|
|
| 74 |
|
|
| - |
|
Net loss |
| $ | (26,201 | ) |
| $ | (13,566 | ) |
| $ | (91,822 | ) |
| $ | (41,240 | ) |
Other comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Foreign currency translation adjustments |
|
| (172 | ) |
|
| (40 | ) |
|
| (412 | ) |
|
| (22 | ) |
Total other comprehensive loss |
|
| (172 | ) |
|
| (40 | ) |
|
| (412 | ) |
|
| (22 | ) |
Total comprehensive loss |
| $ | (26,373 | ) |
| $ | (13,606 | ) |
| $ | (92,234 | ) |
| $ | (41,262 | ) |
Net loss per share basic and diluted |
| $ | (0.98 | ) |
| $ | (0.52 | ) |
| $ | (3.46 | ) |
| $ | (1.59 | ) |
Weighted-average number of shares used in calculating net |
|
| 26,697,226 |
|
|
| 25,987,648 |
|
|
| 26,532,159 |
|
|
| 25,891,045 |
|
VAPOTHERM, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) | ||||||||
|
|
|
|
|
|
| ||
|
| Nine Months Ended September 30, |
| |||||
|
| 2022 |
|
| 2021 |
| ||
Cash flows from operating activities |
|
|
|
|
|
| ||
Net loss |
| $ | (91,822 | ) |
| $ | (41,240 | ) |
Adjustments to reconcile net loss to net cash used in operating activities |
|
|
|
|
|
| ||
Stock-based compensation expense |
|
| 7,625 |
|
|
| 7,197 |
|
Depreciation and amortization |
|
| 4,006 |
|
|
| 4,181 |
|
Provision for bad debts |
|
| 346 |
|
|
| (110 | ) |
Provision for inventory valuation |
|
| 2,655 |
|
|
| - |
|
Non-cash lease expense |
|
| 1,670 |
|
|
| 1,304 |
|
Change in fair value of contingent consideration |
|
| (3,351 | ) |
|
| (457 | ) |
Impairment of goodwill |
|
| 14,701 |
|
|
| - |
|
Impairment of long-lived and intangible assets |
|
| 6,175 |
|
|
| - |
|
Loss on disposal of property and equipment |
|
| 546 |
|
|
| 126 |
|
Amortization of discount on debt |
|
| 502 |
|
|
| 55 |
|
Deferred income taxes |
|
| 74 |
|
|
| 12 |
|
Loss on extinguishment of debt |
|
| 1,114 |
|
|
| - |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
| ||
Accounts receivable |
|
| 2,338 |
|
|
| 2,776 |
|
Inventories |
|
| (2,651 | ) |
|
| (4,861 | ) |
Prepaid expenses and other assets |
|
| (1,902 | ) |
|
| (1,102 | ) |
Accounts payable |
|
| (4,295 | ) |
|
| (854 | ) |
Contract liabilities |
|
| (562 | ) |
|
| (658 | ) |
Accrued expenses and other current liabilities |
|
| (4,853 | ) |
|
| (4,286 | ) |
Operating lease liabilities, current and long-term |
|
| (1,581 | ) |
|
| (1,305 | ) |
Net cash used in operating activities |
|
| (69,265 | ) |
|
| (39,222 | ) |
Cash flows from investing activities |
|
|
|
|
|
| ||
Purchases of property and equipment |
|
| (8,266 | ) |
|
| (4,814 | ) |
Net cash used in investing activities |
|
| (8,266 | ) |
|
| (4,814 | ) |
Cash flows from financing activities |
|
|
|
|
|
| ||
Proceeds from loans, net of discount |
|
| 99,094 |
|
|
| - |
|
Repayment of loans |
|
| (40,000 | ) |
|
| - |
|
Payments of debt extinguishment costs |
|
| (817 | ) |
|
| - |
|
Payment of debt issuance costs |
|
| (1,567 | ) |
|
| - |
|
Repayments on revolving loan facility |
|
| (6,608 | ) |
|
| (3,163 | ) |
Payment of contingent consideration |
|
| (135 | ) |
|
| - |
|
Proceeds from exercise of stock options |
|
| 65 |
|
|
| 1,405 |
|
Proceeds from issuance of common stock under Employee Stock Purchase Plan |
|
| 135 |
|
|
| 851 |
|
Net cash provided by (used in) financing activities |
|
| 50,167 |
|
|
| (907 | ) |
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
|
| (142 | ) |
|
| (5 | ) |
Net decrease in cash, cash equivalents and restricted cash |
|
| (27,506 | ) |
|
| (44,948 | ) |
Cash, cash equivalents and restricted cash |
|
|
|
|
|
| ||
Beginning of period |
|
| 57,324 |
|
|
| 115,536 |
|
End of period |
| $ | 29,818 |
|
| $ | 70,588 |
|
Supplemental disclosures of cash flow information |
|
|
|
|
|
| ||
Interest paid during the period |
| $ | 6,023 |
|
| $ | 1,862 |
|
Property and equipment purchases in accounts payable and accrued expenses |
| $ | 617 |
|
| $ | 133 |
|
Issuance of common stock to satisfy contingent consideration |
| $ | 5,630 |
|
| $ | - |
|
Issuance of common stock warrants in conjunction with long term debt |
| $ | 1,196 |
|
| $ | - |
|
Issuance of common stock upon vesting of restricted stock units |
| $ | 15 |
|
| $ | 133 |
|
Non-GAAP Financial Measures
The following tables contain a reconciliation of net loss to Adjusted EBITDA for the three months ended September 30, 2022 and 2021, respectively.
(unaudited)
|
| Three Months Ended September 30, |
| |||||
|
| 2022 |
|
| 2021 |
| ||
|
| (in thousands) |
| |||||
Net loss |
| $ | (26,201 | ) |
| $ | (13,566 | ) |
Interest expense, net |
|
| 3,220 |
|
|
| 626 |
|
Benefit for income taxes |
|
| (8 | ) |
|
| - |
|
Depreciation and amortization |
|
| 1,267 |
|
|
| 1,318 |
|
EBITDA |
| $ | (21,722 | ) |
| $ | (11,622 | ) |
Foreign currency |
|
| 73 |
|
|
| 58 |
|
Change in fair value of contingent consideration |
|
| (238 | ) |
|
| (1,220 | ) |
Stock-based compensation |
|
| 1,681 |
|
|
| 2,079 |
|
Impairment of long-lived and intangible assets |
|
| 2,139 |
|
|
| - |
|
Loss on disposal of property and equipment |
|
| 321 |
|
|
| - |
|
Adjusted EBITDA |
| $ | (17,746 | ) |
| $ | (10,705 | ) |
The following tables contain a reconciliation of operating expenses to cash operating expenses for the three months ended September 30, 2022, June 30, 2022 and September 30, 2021, respectively.
(unaudited)
|
| Three Months Ended |
| |||||||||
|
| September 30, |
|
| June 30, |
|
| September 30, |
| |||
|
| (in thousands) |
| |||||||||
GAAP operating expenses |
| $ | 24,779 |
|
| $ | 42,203 |
|
| $ | 31,706 |
|
Impairment of goodwill |
|
| - |
|
|
| (14,701 | ) |
|
| - |
|
Impairment of long-lived and intangible assets |
|
| (2,139 | ) |
|
| (4,036 | ) |
|
| - |
|
Loss on disposal of property and equipment |
|
| (321 | ) |
|
| - |
|
|
| - |
|
Stock-based compensation |
|
| (1,488 | ) |
|
| (2,304 | ) |
|
| (1,898 | ) |
Termination benefits |
|
| (1,186 | ) |
|
| (1,844 | ) |
|
| - |
|
Depreciation and amortization |
|
| (395 | ) |
|
| (500 | ) |
|
| (467 | ) |
Change in fair value of contingent consideration |
|
| 238 |
|
|
| 2,925 |
|
|
| 1,220 |
|
Non-GAAP cash operating expenses |
| $ | 19,488 |
|
| $ | 21,743 |
|
| $ | 30,561 |
|
Supplemental Operating Metrics
| September 30, |
|
|
|
|
|
|
| |||||||
| 2022 |
|
| 2021 |
|
| Change |
| |||||||
| Amount |
|
| Amount |
|
| Amount |
|
| % |
| ||||
HVT 2.0 and precision flow units installed base |
|
|
|
|
|
|
|
|
|
|
| ||||
United States |
| 23,998 |
|
|
| 22,911 |
|
|
| 1,087 |
|
|
| 4.7 | % |
International |
| 12,328 |
|
|
| 11,623 |
|
|
| 705 |
|
|
| 6.1 | % |
Total |
| 36,326 |
|
|
| 34,534 |
|
|
| 1,792 |
|
|
| 5.2 | % |
|
|
|
|
|
|
|
|
|
|
|
| ||||
| Three Months Ended September 30, |
|
|
|
|
|
|
| |||||||
| 2022 |
|
| 2021 |
|
| Change |
| |||||||
| Amount |
|
| Amount |
|
| Amount |
|
| % |
| ||||
HVT 2.0 and precision flow units sold and leased |
|
|
|
|
|
|
|
|
|
|
| ||||
United States |
| 123 |
|
|
| 1,891 |
|
|
| (1,768 | ) |
|
| (93.5 | )% |
International |
| 51 |
|
|
| 556 |
|
|
| (505 | ) |
|
| (90.8 | )% |
Total |
| 174 |
|
|
| 2,447 |
|
|
| (2,273 | ) |
|
| (92.9 | )% |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Disposable patient circuits sold |
|
|
|
|
|
|
|
|
|
|
| ||||
United States |
| 71,818 |
|
|
| 168,471 |
|
|
| (96,653 | ) |
|
| (57.4 | )% |
International |
| 20,854 |
|
|
| 31,501 |
|
|
| (10,647 | ) |
|
| (33.8 | )% |
Total |
| 92,672 |
|
|
| 199,972 |
|
|
| (107,300 | ) |
|
| (53.7 | )% |
|
|
|
|
|
|
|
|
|
|
|
|
View source version on businesswire.com:https://www.businesswire.com/news/home/20221102005652/en/
CONTACT: Investor Relations Contacts:
Mark Klausner or Mike Vallie, Westwicke, an ICR Company,ir@vtherm.com, +1 (603) 658-0011
KEYWORD: UNITED STATES NORTH AMERICA NEW HAMPSHIRE
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL DEVICES OTHER HEALTH HEALTH MEDICAL SUPPLIES
SOURCE: Vapotherm, Inc.
Copyright Business Wire 2022.
PUB: 11/02/2022 04:10 PM/DISC: 11/02/2022 04:11 PM
http://www.businesswire.com/news/home/20221102005652/en